Vigil Neuroscience, Inc. (NASDAQ:VIGL - Get Free Report) CEO Ivana Magovcevic-Liebisch bought 5,000 shares of the firm's stock in a transaction that occurred on Thursday, December 5th. The stock was purchased at an average cost of $2.34 per share, with a total value of $11,700.00. Following the completion of the purchase, the chief executive officer now directly owns 212,687 shares of the company's stock, valued at $497,687.58. This represents a 2.41 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Vigil Neuroscience Stock Up 2.2 %
NASDAQ VIGL opened at $2.31 on Friday. The stock's 50-day simple moving average is $3.33 and its two-hundred day simple moving average is $3.60. Vigil Neuroscience, Inc. has a twelve month low of $2.08 and a twelve month high of $6.06. The company has a market capitalization of $94.43 million, a price-to-earnings ratio of -1.12 and a beta of 1.65.
Wall Street Analyst Weigh In
VIGL has been the topic of several research reports. HC Wainwright reaffirmed a "buy" rating and issued a $17.00 price objective on shares of Vigil Neuroscience in a research note on Friday, November 8th. Wedbush raised their target price on Vigil Neuroscience from $23.00 to $24.00 and gave the stock an "outperform" rating in a research note on Friday, November 8th. JMP Securities reiterated a "market outperform" rating and set a $22.00 price objective on shares of Vigil Neuroscience in a report on Tuesday, November 26th. William Blair assumed coverage on Vigil Neuroscience in a report on Wednesday. They issued an "outperform" rating on the stock. Finally, Guggenheim cut their price target on Vigil Neuroscience from $17.00 to $16.00 and set a "buy" rating for the company in a research note on Wednesday, August 14th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $16.60.
First JFK… next Elon?
From Porter & Company | Ad
Today, I have another controversial prediction.
One which I will take no pleasure in seeing come true.
See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.
I share with you in this special investigative documentary.
View Our Latest Analysis on Vigil Neuroscience
Hedge Funds Weigh In On Vigil Neuroscience
Large investors have recently modified their holdings of the company. Ensign Peak Advisors Inc grew its position in Vigil Neuroscience by 72.8% during the second quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company's stock valued at $1,580,000 after acquiring an additional 166,442 shares during the last quarter. abrdn plc purchased a new stake in shares of Vigil Neuroscience in the 3rd quarter valued at $799,000. Point72 Asset Management L.P. purchased a new stake in shares of Vigil Neuroscience in the 2nd quarter valued at $5,940,000. Vanguard Group Inc. raised its position in Vigil Neuroscience by 11.9% in the 1st quarter. Vanguard Group Inc. now owns 894,473 shares of the company's stock worth $3,050,000 after purchasing an additional 95,276 shares during the period. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in Vigil Neuroscience in the second quarter worth $87,000. 83.64% of the stock is owned by hedge funds and other institutional investors.
About Vigil Neuroscience
(
Get Free Report)
Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
